ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR

Array BioPharma has announced the initiation of a Phase I clinical trial for its proprietary small molecule, ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease.

ARRY-438162 will be evaluated in dose escalation studies in normal, healthy volunteers. Array scientists demonstrated ARRY-438162 to be potent, selective, well-tolerated and efficacious in preclinical models of human inflammatory diseases.